EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Liposomal formulation of a new antifungal hybrid compound provides protection against Candida auris in the ex vivo skin colonization model

Anna Jaromin iD, Robert Zarnowski iD, Adam Markowski, Agnieszka Zagórska, Chad J Johnson, Haniyeh Etezadi, Shinji Kihara, Pablo Mota-Santiago, Jeniel E Nett iD, Ben J Boyd iD, David R Andes iD

Antimicrobial Agents and Chemotherapy · 2024

DOI: 10.1128/aac.00955-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Anna Jaromin und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Lipids and Liposomes, Faculty of Biotechnology, University of Wrocław , Wrocław, Poland. Hauptthemen laut MEDLINE: Antifungal Agents, Candida. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, The Excellence Initiative - Research University program for the University of Wrocław, Polish National Agency for Academic Exchange.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The newly emerged pathogen, Candida auris , presents a serious threat to public health worldwide. This multidrug-resistant yeast often colonizes and persists on the skin of patients, can easily spread from person to person, and can cause life-threatening systemic infections. New antifungal therapies are therefore urgently needed to limit and control both superficial and systemic C. auris infections. In this study, we designed a novel antifungal agent, PQA-Az-13, that contains a combination of indazole, pyrrolidine, and arylpiperazine scaffolds substituted with a trifluoromethyl moiety. PQA-Az-13 demonstrated antifungal activity against biofilms of a set of 10 different C. auris clinical isolates, representing all four geographical clades distinguished within this species. This compound showed strong activity, with MIC values between 0.67 and 1.25 µg/mL. Cellular proteomics indicated that PQA-Az-13 partially or completely inhibited numerous enzymatic proteins in C. auris biofilms, particularly those involved in both amino acid biosynthesis and metabolism processes, as well as in general energy-producing processes. Due to its hydrophobic nature and limited aqueous solubility, PQA-Az-13 was encapsulated in cationic liposomes composed of soybean phosphatidylcholine (SPC), 1,2-dioleoyloxy-3-trimethylammonium-propane chloride (DOTAP), and N -(carbonyl-methoxypolyethylene glycol-2000)-1,2-distearoyl- sn -glycero-3-phosphoethanolamine, sodium salt (DSPE-PEG 2000), and characterized by biophysical and spectral techniques. These PQA-Az-13-loaded liposomes displayed a mean size of 76.4 nm, a positive charge of +45.0 mV, a high encapsulation efficiency of 97.2%, excellent stability, and no toxicity to normal human dermal fibroblasts. PQA-Az-13 liposomes demonstrated enhanced antifungal activity levels against both C. auris in in vitro biofilms and ex vivo skin colonization models. These initial results suggest that molecules like PQA-Az-13 warrant further study and development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antifungal AgentsCandidaHumansCandida aurisLiposomesMicrobial Sensitivity TestsBiofilms

Stichwörter der Autor:innen

Candida aurisantifungalbiofilmfungal skin infectionliposomesproteomics

Substanzen

Antifungal AgentsLiposomes

Autor:innen und Institutionen

  • Department of Lipids and Liposomes, Faculty of Biotechnology, University of Wrocław , Wrocław, Poland.
  • Department of Medicine, School of Medicine & Public Health, University of Wisconsin-Madison , Madison, Wisconsin, USA.
  • Department of Medical Microbiology, School of Medicine & Public Health, University of Wisconsin-Madison , Madison, Wisconsin, USA.
  • Department of Medicinal Chemistry, Jagiellonian University Medical College , Cracow, Poland.
  • Department of Medicine, University of Wisconsin , Madison, Wisconsin, USA.
  • Department of Pharmacy, University of Copenhagen , Copenhagen, Denmark.

ORCID-Profile: Anna Jaromin, Robert Zarnowski, Jeniel E Nett, Ben J Boyd, David R Andes

Förderung

  • NIAID NIH HHS
  • The Excellence Initiative - Research University program for the University of Wrocław
  • Polish National Agency for Academic Exchange
  • Italian Ministry of Foreign Affairs and International Cooperation
  • HHS | NIH | National Institute of Allergy and Infectious Diseases
  • Novo Nordisk Foundation

Zitieren

APA

Jaromin, A., Zarnowski, R., Markowski, A., Zagórska, A., Johnson, C. J., Etezadi, H., Kihara, S., Mota-Santiago, P., Nett, J. E., Boyd, B. J., & Andes, D. R. (2024). Liposomal formulation of a new antifungal hybrid compound provides protection against Candida auris in the ex vivo skin colonization model. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00955-23

Vancouver

Jaromin A, Zarnowski R, Markowski A, Zagórska A, Johnson CJ, Etezadi H, et al. Liposomal formulation of a new antifungal hybrid compound provides protection against Candida auris in the ex vivo skin colonization model. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.00955-23

BibTeX
@article{Jaromin2024,
  author = {Jaromin, Anna and Zarnowski, Robert and Markowski, Adam and Zagórska, Agnieszka and Johnson, Chad J and Etezadi, Haniyeh and Kihara, Shinji and Mota-Santiago, Pablo and Nett, Jeniel E and Boyd, Ben J and Andes, David R},
  title = {Liposomal formulation of a new antifungal hybrid compound provides protection against Candida auris in the ex vivo skin colonization model},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2024},
  doi = {10.1128/aac.00955-23}
}
Kostenlos starten →